Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a note issued to investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $23.00 price target on the stock. Jefferies Financial Group’s price target suggests a potential upside of 201.44% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Piper Sandler began coverage on Avalo Therapeutics in a research note on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a research report on Tuesday. They set a “buy” rating and a $36.00 price objective for the company. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Stock Performance

Shares of NASDAQ:AVTX opened at $7.63 on Tuesday. The firm has a fifty day moving average price of $7.47 and a 200 day moving average price of $9.13. Avalo Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors have recently made changes to their positions in the company. Velan Capital Investment Management LP bought a new stake in Avalo Therapeutics during the 4th quarter valued at $817,000. BVF Inc. IL increased its holdings in shares of Avalo Therapeutics by 7.2% during the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock valued at $7,703,000 after acquiring an additional 69,679 shares in the last quarter. Allostery Investments LP purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at $545,000. Northern Trust Corp purchased a new position in shares of Avalo Therapeutics in the fourth quarter worth about $168,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.